Detailed Narrative
Q1 FY26 Performance Overview
3B Blackbio reported a robust Q1 FY26 with sales reaching INR 19.96 crores, an 18% increase compared to INR 16.94 crores in Q1 last year. EBITDA for the quarter was INR 16.19 crores, showing an 11% year-on-year growth. Excluding a one-time📎 M&A expense of INR 80 lakhs, the adjusted EBITDA growth was 17%, indicating strong underlying operational performance.
Strategic Acquisition of Coris Bioconcept
The company announced the acquisition of Coris Holding SRL, parent of Coris Bioconcept, for an upfront cash consideration of GBP 2.15 million, with an additional earn-out of up to GBP 2.615 million. Coris, a 30-year-old manufacturer of rapid diagnostic solutions, reported EUR 5.22 million in top line with a 58.7% gross margin but was EBITDA negative at EUR 0.215 million. This acquisition is strategic, aiming to expand 3B Blackbio's geographical reach into Europe and strengthen its product portfolio, particularly in Antimicrobial Resistance (AMR).
Growth Strategy for Indian MDX Business
The Indian molecular diagnostics (MDX) industry is projected to grow at an 8-10% CAGR. 3B Blackbio aims to outpace this, targeting 15-20% growth for its Indian MDX business in FY25-26, driven by its extensive product portfolio and strong market presence. However, management anticipates a slight compression in EBITDA margin for the Indian business, from 60% to 55%, due to increasing competition and inflationary pressures.
International Expansion and Export Strategy
The company expects its exports to grow by 20-25% over the next 2-3 years. Specifically, TRUPCR exports are projected to reach INR 17-18 crores this year, up from INR 13.91 crores last year, representing a 30% growth. The UK subsidiary plays a crucial role in catering to European customers, providing technical support and maintaining inventory, which enhances customer confidence and reliability. The long-term vision is to increase the export share of revenue to 35-40% within the next five years.
R&D and Product Pipeline
3B Blackbio emphasizes its strong R&D capabilities, which enable the development of unique multi-tube assays, such as respiratory, meningitis, and neuro panels. The company's ability to rapidly develop assays, as demonstrated during Monkeypox and COVID-19, is a key differentiator. Coris also brings a strong R&D pipeline, particularly in AMR, which will contribute to future top-line growth. Management plans to launch new products from Coris's pipeline within the next 6-12 months.
Capital Allocation and Debt Management
The MDX business is not highly capital intensive. The company has sufficient capacity, with current utilization at 65%, and foresees minimal capex of INR 1-2 crores for facility upgrades or equipment over the next two years. Coris has a debt of INR 4-5 crores, which is expected to be repaid over the next two years, and a cash balance of EUR 1.2-1.5 million, sufficient for its operations. 3B Blackbio continues to actively seek new M&A targets globally, leveraging its available funds.
Industry Dynamics and Competitive Landscape
The molecular diagnostics market in India is still nascent but growing, with increasing adoption in labs and hospitals. While the industry attracts competition, 3B Blackbio differentiates itself through product quality, service, and strong R&D. Management addressed potential threats from microfluidic POC and isothermal amplification technologies, stating they are not immediate risks to their high-volume lab focus but are part of their R&D considerations for future relevance. IVDR compliance for Coris products is a key regulatory focus, with associated costs already factored into their structure.